



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/11, A61K 31/70, C07H 21/00	A1	(11) International Publication Number: WO 97/21808 (43) International Publication Date: 19 June 1997 (19.06.97)
(21) International Application Number: PCT/US96/19320 (22) International Filing Date: 5 December 1996 (05.12.96) (30) Priority Data: 08/569,926 8 December 1995 (08.12.95) US (71) Applicant: HYBRIDON, INC. [US/US]; One Innovation Drive, Worcester, MA 01605 (US). (72) Inventor: ROBINSON, Gregory, S.; 194 School Street, Acton, MA 01720 (US). (74) Agents: KERNER, Ann-Louise; Hale and Dorr, Sixty State Street, Boston, MA 02109 (US) et al.		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: MODIFIED VEGF ANTISENSE OLIGONUCLEOTIDES (57) Abstract Disclosed are oligonucleotides complementary to VEGF-specific nucleic acid useful in reducing the expression of VEGF. Also disclosed are pharmaceutical formulations containing such oligonucleotides useful for treating various disorders associated with neovascularization and angiogenesis.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

MODIFIED VEGF ANTISENSE OLIGONUCLEOTIDES

CROSS-REFERENCE TO RELATED APPLICATIONS

5 This application is a continuation-in-part of
compending Patent Application Serial No. 08/398,945
entitled "Human VEGF-Specific Oligonucleotides,"
filed March 2, 1995, which is a continuation-in-
part of compending Patent Application Serial No.
08/378,860 entitled "Inhibition of Neovasculariza-
tion Using VEGF-Specific Oligonucleotides", filed
10 26 January, 1995, which is a continuation-in-part
of compending Patent Application Serial No.
08/098,942 entitled "Antisense Oligonucleotide
Inhibition of Vascular Endothelial Growth Factor
Expression, filed 27 July, 1993.

15

BACKGROUND OF THE INVENTION

This invention relates to vascular
endothelial growth factor. More specifically,
20 this invention relates to oligonucleotides
specific for vascular endothelial growth factor
nucleic acid and useful treatment of disorders
that are associated with neovascularization and
angiogenesis.

25

Neovascular diseases of the retina such as
diabetic retinopathy, retinopathy of prematurity,
and age-related macular degeneration are a major
cause of blindness in the United States and the
30 world, yet the biochemical events responsible for
these processes have not been fully elucidated.

Diabetic retinopathy is the leading cause of blindness among working age adults (20-64) in the United States (Foster in *Harrison's Principles of Internal Medicine* (Isselbacher et al., eds.) McGraw-Hill, Inc., New York (1994) pp. 1994-1995). During the course of diabetes mellitus, the retinal vessels undergo changes that result in not only leaky vessels but also vessel drop out resulting in retinal hypoxia. The effects of these complications are hemorrhaging, "cotton wool" spots, retinal infarcts, and neovascularization of the retina resulting in bleeding and retinal detachment. If left untreated, there is a 60% chance of visual loss. Classic treatment for proliferative diabetic retinopathy is panretinal laser photocoagulation (PRP). However, complications can occur from panretinal laser photocoagulation such as foveal burns, hemorrhaging, retinal detachment, and choroidal vessel growth. Furthermore, other untoward effects of this treatment are decreased peripheral vision, decreased night vision, and changes in color perception (*Am. J. Ophthalmol.* (1976) **81**:383-396; *Ophthalmol.* (1991) **98**:741-840). Thus, there is a need for a more effective treatment for diabetic retinopathy.

Retinopathy of prematurity (ROP) is a common cause of blindness in children in the United States (Pierce et al. (1994) *Int. Ophth. Clinics* **34**:121-148). Premature babies are exposed to hyperoxic conditions after birth even without supplemental oxygen because the partial pressure of oxygen

in utero is much lower than what is achieved when breathing normal room air. This relative hyperoxia is necessary for their survival yet can result in ROP. The blood vessels of the retina
5 cease to develop into the peripheral retina resulting in ischemia and localized hypoxic conditions as the metabolic demands of the developing retina increase. The resulting hypoxia stimulates the subsequent neovascularization of
10 the retina. This neovascularization usually regresses but can lead to irreversible vision loss. There are at least 10,000 new cases per year with a worldwide estimate of 10 million total cases. At present, there is no effective cure for
15 ROP. Two therapeutic methods, cryotherapy and laser therapy, have been used but are not completely effective and themselves cause damage to the eye, resulting in a reduction of vision (Pierce et al. (1994) *Int. Ophth. Clinics* **34**:121-148).
20 Many other antiangiogenic compounds have been tested, but no inhibition in retinal neovascularization has been reported (Smith et al. (1994) *Invest. Ophthalmol. Vis. Sci.* **35**:1442; Foley et al. (1994) *Invest. Ophthalmol. Vis. Sci.* **35**:1442).
25 Thus, there is a need for an effective treatment for ROP.

Age related macular degeneration is one of the leading causes of blindness in older adults in
30 the United States, and may account for up to 30% of all bilateral blindness among Caucasian Americans (Anonymous (1994) *Prevent Blindness America*). This disease is characterized by loss of central

vision, usually in both eyes, due to damage to retinal pigment epithelial cells which provide physiological support to the light sensitive photoreceptor cells of the retina. In most cases there is currently no effective treatment. In approximately 20% of exudative cases that are diagnosed early, laser treatment can prevent further loss of vision; however, this effect is temporary (Bressler et al., *Principles and Practices of Ophthalmology* (eds. Albert and Jakobiec), W.B. Saunders Co., Philadelphia, PA) (1994) Vol. 2 pp. 834-852). Thus, there is a need for a more effective and permanent treatment for age related macular degeneration.

Ocular neovascularization is also the underlying pathology in sickle cell retinopathy, neovascular glaucoma, retinal vein occlusion, and other hypoxic diseases. These eye diseases as well as other pathological states associated with neovascularization (i.e., tumor growth, wound healing) appear to have hypoxia as a common factor (Knighton et al. (1983) *Science* **221**:1283-1285; Folkman et al. (1987) *Science* **235**:442-446; Klagsbrun et al. (1991) *Ann. Rev. Physiol.* **53**:217-239; Miller et al. (1993) *Principles and Practice of Ophthalmology*, W.B. Saunders, Philadelphia, pp. 760; and Aiello et al. (1994) *New Eng. J. Med.* **331**:1480-1487). Moreover, retinal neovascularization has been hypothesized to be the result of a "vasoformative factor" which is released by the retina in response to hypoxia (Michaelson (1948) *Trans. Ophthalmol. Soc. U. K.* **68**:137-180; and Ashton et al. (1954) *Br. J. Ophthalmol.*

38:397-432). Recent experimental data show a high correlation between vascular endothelial growth factor expression and retinal neovascularization (Aiello et al. (1994) *New Eng. J. Med.* **331**:1480-1487). Furthermore, elevated levels of vascular endothelial growth factor have recently been found in vitreous from patients with diabetes (Aiello et al., *ibid.*). Thus, this cytokine/growth factor may play an important role in neovascularization-related disease.

Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) is an endothelial cell-specific mitogen which has recently been shown to be stimulated by hypoxia and required for tumor angiogenesis (Senger et al. (1986) *Cancer* **46**:5629-5632; Kim et al. (1993) *Nature* **362**:841-844; Schweiki et al. (1992) *Nature* **359**:843-845; Plate et al. (1992) *Nature* **359**:845-848). It is a 34-43 kD (with the predominant species at about 45 kD) dimeric, disulfide-linked glycoprotein synthesized and secreted by a variety of tumor and normal cells. In addition, cultured human retinal cells such as pigment epithelial cells and pericytes have been demonstrated to secrete VEGF and to increase VEGF gene expression in response to hypoxia (Adamis et al. (1993) *Biochem. Biophys. Res. Commun.* **193**:631-638; Plouet et al. (1992) *Invest. Ophthalmol. Vis. Sci.* **34**:900; Adamis et al. (1993) *Invest. Ophthalmol. Vis. Sci.* **34**:1440; Aiello et al. (1994) *Invest. Ophthalmol. Vis. Sci.* **35**:1868; Simorre-Pinatel et al. (1994) *Invest. Ophthalmol. Vis. Sci.* **35**:3393-3400). In

contrast, VEGF in normal tissues is relatively low. Thus, VEGF appears to play a principle role in many pathological states and processes related to neovascularization. Regulation of VEGF
5 expression in tissues affected by the various conditions described above could therefore be key in treatment or preventative therapies associated with hypoxia.

10 New chemotherapeutic agents termed "antisense oligonucleotides" have been developed which are capable of modulating cellular and foreign gene expression (see, Zamecnik et al. (1978) *Proc. Natl. Acad. Sci. (USA)* **75**:280-284). Without being limited
15 to any theory or mechanism, it is generally believed that the activity of antisense oligonucleotides depends on the binding of the oligonucleotide to the target nucleic acid (e.g. to at least a portion of a genomic region, gene or
20 mRNA transcript thereof), thus disrupting the function of the target, either by hybridization arrest or by destruction of target RNA by RNase H (the ability to activate RNase H when hybridized to RNA).

25 VEGF-specific antisense oligonucleotides have been developed (Uchida et al. (1995) *Antisense Res. & Dev.* **5(1):87** (Abstract OP-10); Nomura et al., (1995) *Antisense Res. & Dev.* **5(1):91** (Abstract OP-18)),
30 although none have been demonstrated to reverse neovascularization or angiogenesis. Thus, a need still remains for the development of oligonucleotides that are capable of reducing VEGF

expression, and ultimately, of inhibiting the onset of diseases and disorders associated with the expression of VEGF.

SUMMARY OF THE INVENTION

It is known that cells affected by hypoxia induce VEGF. The present invention provides novel synthetic oligonucleotides specific nucleotides 58 to 90 of the VEGF gene which can reduce the hypoxia-induced expression of VEGF mRNA and protein. This information has been exploited to develop the present invention which includes VEGF-specific oligonucleotides, pharmaceutical formulation, and methods of reducing the expression of VEGF mRNA and protein.

In one aspect, the invention provides a synthetic oligonucleotide complementary to a nucleic acid specific for human vascular endothelial growth factor. This oligonucleotide has a nucleic acid sequence set forth in the Sequence Listing as SEQ ID NOS:2-16.

As used herein, the term "synthetic oligonucleotide" refers to chemically synthesized polymers of nucleotides covalently attached via at least one 5' to 3' internucleotide linkage. In some embodiments, these oligonucleotides contain at least one deoxyribonucleotide, ribonucleotide, or both deoxyribonucleotides and ribonucleotides. In another embodiment, the synthetic oligonucleotides used in the methods of the invention are from about 15 to about 30 nucleotides in length. In preferred embodiments, these oligonucleotides contain from about 16 to 29 nucleotides.

For purposes of the invention, the term "oligonucleotide sequence that is complementary to a genomic region or an RNA molecule transcribed therefrom" is intended to mean an oligonucleotide
5 that binds to the nucleic acid sequence under physiological conditions, e.g., by Watson-Crick base pairing (interaction between oligonucleotide and single-stranded nucleic acid) or by Hoogsteen base pairing (interaction between oligonucleotide
10 and double-stranded nucleic acid) or by any other means including in the case of a oligonucleotide binding to RNA, causing pseudoknot formation. Binding by Watson-Crick or Hoogsteen base pairing under physiological conditions is measured as a
15 practical matter by observing interference with the function of the nucleic acid sequence.

In some embodiments, the synthetic oligonucleotide of the invention are modified in a
20 number of ways without compromising their ability to hybridize to nucleotide sequences contained within the mRNA for VEGF. The term "modified oligonucleotide" as used herein describes an oligonucleotide in which at least two of its
25 nucleotides are covalently linked via a synthetic linkage, i.e., a linkage other than a phosphodiester linkage between the 5' end of one nucleotide and the 3' end of another nucleotide in which the 5' nucleotide phosphate has been
30 replaced with any number of chemical groups. In some preferred embodiments, at least one internucleotide linkage of the oligonucleotide is an alkylphosphonate, phosphorothioate, phosphorodithioate, phosphate ester,

alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetamdate, and/or carboxymethyl ester.

5 The term "modified oligonucleotide" also encompasses oligonucleotides having at least one nucleotide with a modified base and/or sugar, such as a 2'-O-substituted ribonucleotide. For purposes of the invention, the term "2'-O-substituted"

10 means substitution of the 2' position of the pentose moiety with an -O- lower alkyl group containing 1-6 saturated or unsaturated carbon atoms, or with an -O-aryl or allyl group having 2-6 carbon atoms, wherein such alkyl, aryl or allyl

15 group may be unsubstituted or may be substituted, e.g., with halo, hydroxy, trifluoromethyl, cyano, nitro, acyl, acyloxy, alkoxy, carboxyl, carbalkoxyl, or amino groups; or with a hydroxy, an amino or a halo group, but not with a 2'-H

20 group. In some embodiments the oligonucleotides of the invention include four or five ribonucleotides 2'-O-alkylated at their 5' terminus (i.e., 5' 2-O-alkylated ribonucleotides), and/or four or five ribonucleotides 2'-O-

25 alkylated at their 3' terminus (i.e., 3' 2-O-alkylated ribonucleotides). In preferred embodiments, the nucleotides of the synthetic oligonucleotides are linked by a or at least one phosphorothioate internucleotide linkage. The

30 phosphorothioate linkages may be mixed R_p and S_p enantiomers, or they may be stereoregular or substantially stereoregular in either R_p or S_p form (see Iyer et al. (1995) *Tetrahedron Asymmetry* 6:1051-1054).

In another aspect, the invention provides a method of inhibiting VEGF expression. In this method, nucleic acid specific for VEGF is contacted with an oligonucleotide of the invention. As used herein, the term "nucleic acid" encompasses a genomic region or an RNA molecule transcribed therefrom. In some embodiments, the nucleic acid is mRNA.

Without being limited to any theory or mechanism, it is generally believed that the activity of oligonucleotides used in accordance with this invention depends on the hybridization of the oligonucleotide to the target nucleic acid (e.g. to at least a portion of a genomic region, gene or mRNA transcript thereof), thus disrupting the function of the target. Such hybridization under physiological conditions is measured as a practical matter by observing interference with the function of the nucleic acid sequence. Thus, a preferred oligonucleotide used in accordance with the invention is capable of forming a stable duplex (or triplex in the Hoogsteen pairing mechanism) with the target nucleic acid; activate RNase H thereby causing effective destruction of the target RNA molecule, and in addition is capable of resisting nucleolytic degradation (e.g. endonuclease and exonuclease activity) *in vivo*. A number of the modifications to oligonucleotides described above and others which are known in the art specifically and successfully address each of these preferred characteristics.

Also provided by the present invention is a pharmaceutical composition comprising at least one synthetic oligonucleotide of claim 1 in a physiologically acceptable carrier.

5

Another aspect of the invention includes pharmaceutical compositions capable of inhibiting neovascularization and thus are useful in the methods of the invention. These compositions include a synthetic oligonucleotide of the present invention which specifically inhibits the expression of vascular endothelial growth factor and a physiologically and/or pharmaceutically acceptable carrier.

15

The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s). The term "physiologically acceptable" refers to a non-toxic material that is compatible with a biological system such as a cell, cell culture, tissue, or organism.

20

Another aspect of the invention is assessment of the role of VEGF in neovascularization and angiogenesis associated with disease states.

25

BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing and other objects of the present invention, the various features thereof, as well as the invention itself may be more fully understood from the following description, when read together with the accompanying drawings in which:

FIG. 1 is a schematic representation of the regions of the VEGF cDNA sequence that are targeted by oligonucleotides of the invention;

FIG. 2 is a graphic representation of ELISA results demonstrating the ability of oligonucleotides H3-I and H3-J to inhibit VEGF expression induced by cobalt chloride;

FIG. 3 is a graphic representation of ELISA results demonstrating the ability of oligonucleotides H3-D H3-E, H3-F to inhibit VEGF expression induced by cobalt chloride;

FIG. 4 is a graphic representation of ELISA results demonstrating the ability of oligonucleotides H3-G and H3-H to inhibit VEGF expression induced by cobalt chloride;

FIG. 5 is a graphic representation of ELISA results demonstrating the ability of oligonucleotides H3 and H3-I to inhibit VEGF expression induced by cobalt chloride in M21 human melanoma cells *in vitro*; and

FIG. 6 is a graphic representation of ELISA results demonstrating the ability of modified H3 oligonucleotides to inhibit VEGF expression induced by cobalt chloride (H3-K: all 2'-O-methylated phosphorothioate ribonucleotides; H3-L: five 5' 2'-O-alkylated phosphorothioate ribonucleotides, the remainder, phosphorothioate deoxyribonucleotides; H3-M: five 3' 2'-O-alkylated phosphorothioate ribonucleotides, the remainder, phosphorothioate deoxyribonucleotides; and H3-N: five 3' 2'-O-alkylated phosphorothioate ribonucleotides, five 5' 2'-O-alkylated phosphorothioate ribonucleotides, and the remainder, phosphorothioate deoxyribonucleotides).

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The patent and scientific literature referred to herein establishes the knowledge that is
5 available to those with skill in the art. The issued U.S. patents, allowed applications, and references cited herein are hereby incorporated by reference.

10 The present invention provides synthetic antisense oligonucleotides specific for VEGF nucleic acid which are useful in treating diseases and disorders associated with neovascularization and angiogenesis, including retinal
15 neovascularization.

Antisense oligonucleotide technology provides a novel approach to the inhibition of gene expression (see generally, Agrawal (1992) *Trends in*
20 *Biotech.* **10**:152-158; Wagner (1994) *Nature* **372**:333-335; and Stein et al. (1993) *Science* **261**:1004-1012). By binding to the complementary nucleic acid sequence (the sense strand), antisense oligonucleotide are able to inhibit splicing and translation of RNA.
25 In this way, antisense oligonucleotides are able to inhibit protein expression. Antisense oligonucleotides have also been shown to bind to genomic DNA, forming a triplex, and inhibit transcription. Furthermore, a 17mer base sequence
30 statistically occurs only once in the human genome, and thus extremely precise targeting of specific sequences is possible with such antisense oligonucleotides.

It has been determined that the VEGF coding region is comprised of eight exons (Tischer et al. (1994) *J. Biol. Chem.* **266**:11947-11954). Three VEGF transcripts, 121, 165, and 189 amino acids long, have been observed, suggesting that an alternative splicing mechanism is involved (Leung et al. (1989) *Science* **246**:1306-1309; Tischer et al. (1991) *J. Biol. Chem.* **266**:11947-11954). More recently, a fourth VEGF transcript was discovered which has a length encoding 206 amino acids (Houck et al. (1991) *Mol. Endocrinol.* **5**:1806-1814). Transcripts analogous to the 121 and 165 amino acid polypeptides have been identified in the bovine system (Leung et al. (1989) *Science* **246**:1306-1309), and the transcript corresponding to the 165 amino acid transcript have also been identified in the rodent system (Conn et al. (1990) *Proc. Natl. Acad. Sci. (USA)* **87**:1323-1327); Senger et al. (1990) *Cancer Res.* **50**:1774-1778; Claffey et al. (1992) *J. Biol. Chem.* **267**:16317-16322). Nucleic acid sequences encoding three forms of VEGF have also been reported in humans (Tischer et al. (1991) *J. Biol. Chem.* **266**:11947-11954), and comparisons between the human and the murine VEGF have revealed greater than 85% interspecies conservation (Claffey et al. (1992) *J. Biol. Chem.* **267**:16317-16322).

The oligonucleotides of the invention are directed to any portion of the VEGF nucleic acid sequence that effectively acts as a target for inhibiting VEGF expression. The sequence of the gene encoding VEGF has been reported in mice

(Claffey et al., *ibid.*) and for humans (Tischer et al., *ibid.*). These targeted regions of the VEGF gene include any portions of the known exons. In addition, exon-intron boundaries are potentially useful targets for antisense inhibition of VEGF expression. One useful targeted region is around bases 58 to 90. The nucleotide sequences of some representative, non-limiting oligonucleotides specific for human VEGF have SEQ ID NOS:2-16.

The oligonucleotides of the invention are composed of ribonucleotides, deoxyribonucleotides, or a combination of both, with the 5' end of one nucleotide and the 3' end of another nucleotide being covalently linked. These oligonucleotides are at least 14 nucleotides in length, but are preferably 15 to 30 nucleotides long, with 16 to 29mers being the most common.

These oligonucleotides can be prepared by the art recognized methods such as phosphoramidate or H-phosphonate chemistry which can be carried out manually or by an automated synthesizer as described in Uhlmann et al. (*Chem. Rev.* (1990) **90**:534-583) and Agrawal (*Trends Biotechnol.* (1992) **10**:152-158).

The oligonucleotides of the invention may also be modified in a number of ways without compromising their ability to hybridize to VEGF mRNA. For example, the oligonucleotides may contain at least one or a combination of other than phosphodiester internucleotide linkages between the 5' end of one nucleotide and the 3'

end of another nucleotide in which the 5' nucleotide phosphodiester linkage has been replaced with any number of chemical groups. Examples of such chemical groups include

5 alkylphosphonates, phosphorothioates, phosphorodithioates, alkylphosphonothioates, phosphoramidates, phosphate esters, carbamates, acetamdate, carboxymethyl esters, carbonates, and phosphate triesters.

10 For example, US Patent No. 5,149,797 describes traditional chimeric oligonucleotides having a phosphorothioate core region interposed between methylphosphonate or phosphoramidate

15 flanking regions. U.S. Patent Application Ser. No. (47508-559), filed on August 9, 1995 discloses "inverted" chimeric oligonucleotides comprising one or more nonionic oligonucleotide region (e.g. alkylphosphonate and/or phosphoramidate and/or

20 phosphotriester internucleoside linkage) flanked by one or more region of oligonucleotide phosphorothioate. Various oligonucleotides with modified internucleotide linkages can be prepared according to known methods (see, e.g., Goodchild

25 (1990) *Bioconjugate Chem.* **2**:165-187; Agrawal et al., (1988) *Proc. Natl. Acad. Sci. (USA)* **85**:7079-7083; Uhlmann et al. (1990) *Chem. Rev.* **90**:534-583; and Agrawal et al. (1992) *Trends Biotechnol.* **10**:152-158.

30 The phosphorothioate linkages may be mixed Rp and Sp enantiomers, or they may be stereoregular or substantially stereoregular in either Rp or Sp form (see Iyer et al. (1995) *Tetrahedron Asymmetry*

6:1051-1054). Oligonucleotides with phosphorothioate linkages can be prepared using methods well known in the field such as phosphoramidite (see, e.g., Agrawal et al. (1988) *Proc. Natl. Acad. Sci. (USA)* **85**:7079-7083). or by H-phosphonate (see, e.g., Froehler (1986) *Tetrahedron Lett.* **27**:5575-5578) chemistry. The synthetic methods described in Bergot et al. (*J. Chromatog.* (1992) **559**:35-42) can also be used.

10

Oligonucleotides which are self-stabilized are also considered to be modified oligonucleotides useful in the methods of the invention (Tang et al. (1993) *Nucleic Acids Res.* **20**:2729-2735). These oligonucleotides comprise two regions: a target hybridizing region; and a self-complementary region having an oligonucleotide sequence complementary to a nucleic acid sequence that is within the self-stabilized oligonucleotide.

20

Other modifications include those which are internal or at the end(s) of the oligonucleotide molecule and include additions to the molecule of the internucleoside phosphate linkages, such as cholesteryl or diamine compounds with varying numbers of carbon residues between the amino groups and terminal ribose, deoxyribose and phosphate modifications which cleave, or crosslink to the opposite chains or to associated enzymes or other proteins which bind to the genome. Examples of such modified oligonucleotides include oligonucleotides with a modified base and/or sugar

30

such as arabinose instead of ribose, or a 3', 5'-substituted oligonucleotide having a sugar which, at both its 3' and 5' positions is attached to a chemical group other than a hydroxyl group (at its 3' position) and other than a phosphate group (at its 5' position).

Other examples of modifications to sugars include modifications to the 2' position of the ribose moiety which include but are not limited to 2'-O-substituted with an -O- lower alkyl group containing 1-6 saturated or unsaturated carbon atoms, or with an -O-aryl, or allyl group having 2-6 carbon atoms wherein such -O-alkyl, aryl or allyl group may be unsubstituted or may be substituted, (e.g., with halo, hydroxy, trifluoromethyl cyano, nitro acyl acyloxy, alkoxy, carboxy, carbalkoxyl, or amino groups), or with an amino, or halo group. None of these substitutions are intended to exclude the native 2'-hydroxyl group in the case of ribose or 2'-H- in the case of deoxyribose. PCT Publication No. WO 94/02498 discloses traditional hybrid oligonucleotides having regions of 2'-O-substituted ribonucleotides flanking a DNA core region. U.S. Patent Application Serial No. (47508-559), filed August 9, 1995, discloses an "inverted" hybrid oligonucleotide which includes an oligonucleotide comprising a 2'-O-substituted (or 2' OH, unsubstituted) RNA region which is in between two oligodeoxyribonucleotide regions, a structure that "inverted relative to the "traditional" hybrid oligonucleotides. Nonlimiting examples of particularly useful oligonucleotides of the

invention have 2'-O-alkylated ribonucleotides at their 3', 5', or 3' and 5' termini, with at least four or five contiguous nucleotides being so modified. Non-limiting examples of 2'-O-alkylated groups include 2'-O-methyl, 2'-O-ethyl, 2'-O-propyl, and 2'-O-butyls.

Other modified oligonucleotides are capped with a nuclease resistance-conferring bulky substituent at their 3' and/or 5' end(s) , or have a substitution in one nonbridging oxygen per nucleotide. Such modifications can be at some or all of the internucleoside linkages, as well as at either or both ends of the oligonucleotide and/or in the interior of the molecule.

A nonlimiting list of useful oligonucleotides of the invention are listed below in Table 1.

20

TABLE 1

	OLIGO	TARGETED SITE	SEQUENCE (5' → 3')	SEQ
				ID NO.:
25	H-3Ia1	81-62	GCACCCAAGACAGCAGAAAG	2
	H-3Ia2	81-62	GCACCCAAGACAGCAGAAAG	2
	H-3Ia3	81-62	GCACCCAAGACAGCAG AAAG	2
	H-3Ia4	81-62	GCACCCAAGACAGCAGAAAG	2
30	H-3Ia5	81-62	GCACCCAAGACAGCAGAAAG	2
	H-3Ia6	81-62	GCACCCAAGACAGCAG AAAG	2
	H-3Ia7	81-62	GCACCCAAGACAGCAGAAAG	2
	H-3Ia8	81-62	GCACCCAAGACAGCAGAAAG	2
	H-3Ia9	81-62	GCACCCAAGACAGCAGAAAG	2
35	H-3Ia10	81-62	GCACCCAAGACAGCAGAAAG	2

TABLE 1 (conti'.)

	OLIGO	TARGETED SITE	SEQUENCE (5' → 3')	SEQ ID NO:
5	H-3I1	82-62	TGCACCCAAGACAGCAGAAAG	3
	H-3I2	82-62	TGCACCCAAGACAGCAGAAAG	3
	H-3I3	82-62	TGCACCCAAGACAGCAGAAAG	3
	H-3I4	82-62	TGCACCCAAGACAGCAGAAAG	3
10	H-3I5	82-62	TGCACCCAAGACAGCAGAAAG	3
	H-3I6	82-62	TGCACCCAAGACAGCAGAAAG	3
	H-3I7	82-62	TGCACCCAAGACAGCAGAAAG	3
	H-3I8	82-62	TGCACCCAAGACAGCAGAAAG	3
	H-3I9	82-62	TGCACCCAAGACAGCAGAAAG	3
15	H-3I10	82-62	TGCACCCAAGACAGCAGAAAG	3
	H-3Ja1	83-62	ATGCACCCAAGACAGCAGAAAG	4
	H-3Ja2	83-62	ATGCACCCAAGACAGCAGAAAG	4
	H-3Ja3	83-62	ATGCACCCAAGACAGCAGAAAG	4
	H-3Ja4	83-62	ATGCACCCAAGACAGCAGAAAG	4
20	H-3Ja5	83-62	ATGCACCCAAGACAGCAGAAAG	4
	H-3Ja6	83-62	ATGCACCCAAGACAGCAGAAAG	4
	H-3Ja7	83-62	ATGCACCCAAGACAGCAGAAAG	4
	H-3Ja8	83-62	ATGCACCCAAGACAGCAGAAAG	4
	H-3Ja9	83-62	ATGCACCCAAGACAGCAGAAAG	4
25	H-3Ja10	83-62	ATGCACCCAAGACAGCAGAAAG	4
	H-3J1	84-62	AATGCACCCAAGACAGCAGAAAG	5
	H-3J2	84-62	AATGCACCCAAGACAGCAGAAAG	5
	H-3J3	84-62	AATGCACCCAAGACAGCAGAAAG	5
	H-3J4	84-62	AATGCACCCAAGACAGCAGAAAG	5
30	H-3J5	84-62	AATGCACCCAAGACAGCAGAAAG	5
	H-3J6	84-62	AATGCACCCAAGACAGCAGAAAG	5
	H-3J7	84-62	AATGCACCCAAGACAGCAGAAAG	5
	H-3J8	84-62	AATGCACCCAAGACAGCAGAAAG	5
	H-3J9	84-62	AATGCACCCAAGACAGCAGAAAG	5
35	H-3J10	84-62	AATGCACCCAAGACAGCAGAAAG	5
	H-3Xa1	85-62	CAATGCACCCAAGACAGCAGAAAG	6
	H-3Xa2	85-62	CAATGCACCCAAGACAGCAGAAAG	6
	H-3Xa3	85-62	CAATGCACCCAAGACAGCAGAAAG	6
	H-3Xa4	85-62	CAATGCACCCAAGACAGCAGAAAG	6
40	H-3Xa5	85-62	CAATGCACCCAAGACAGCAGAAAG	6
	H-3Xa6	85-62	CAATGCACCCAAGACAGCAGAAAG	6
	H-3Xa7	85-62	CAATGCACCCAAGACAGCAGAAAG	6
	H-3Xa8	85-62	CAATGCACCCAAGACAGCAGAAAG	6
	H-3Xa9	85-62	CAATGCACCCAAGACAGCAGAAAG	6
45	H-3Xa10	85-62	CAATGCACCCAAGACAGCAGAAAG	6
	H-3X1	86-62	CCAATGCACCCAAGACAGCAGAAAG	7
	H-3X2	86-62	CCAATGCACCCAAGACAGCAGAAAG	7
	H-3X3	86-62	CCAATGCACCCAAGACAGCAGAAAG	7
	H-3X4	86-62	CCAATGCACCCAAGACAGCAGAAAG	7
50	H-3X5	86-62	CCAATGCACCCAAGACAGCAGAAAG	7

TABLE 1 (conti'.)

	OLIGO	TARGETED SITE	SEQUENCE (5' → 3')	SEQ ID NO:
5	H-3X6	86-62	CCAATGCACCCAAGACAGCAGAAAG	7
	H-3X7	86-62	CCAATGCACCCAAGACAGCAGAAAG	7
	H-3X8	86-62	CCAATGCACCCAAGACAGCAGAAAG	7
	H-3X9	86-62	CCAATGCACCCAAGACAGCAGAAAG	7
10	H-3X10	86-62	CCAATGCACCCAAGACAGCAGAAAG	7
	H-3Ya1	87-62	TCCAATGCACCCAAGACAGCAGAAAG	8
	H-3Ya2	87-62	TCCAATGCACCCAAGACAGCAGAAAG	8
	H-3Ya3	87-62	TCCAATGCACCCAAGACAGCAGAAAG	8
	H-3Ya4	87-62	TCCAATGCACCCAAGACAGCAGAAAG	8
15	H-3Ya5	87-62	TCCAATGCACCCAAGACAGCAGAAAG	8
	H-3Ya6	87-62	TCCAATGCACCCAAGACAGCAGAAAG	8
	H-3Ya7	87-62	TCCAATGCACCCAAGACAGCAGAAAG	8
	H-3Ya8	87-62	TCCAATGCACCCAAGACAGCAGAAAG	8
	H-3Ya9	87-62	TCCAATGCACCCAAGACAGCAGAAAG	8
20	H-3Ya10	87-62	TCCAATGCACCCAAGACAGCAGAAAG	8
	H-Y1	88-62	CTCCAATGCACCCAAGACAGCAGAAAG	9
	H-Y2	88-62	CTCCAATGCACCCAAGACAGCAGAAAG	9
	H-Y3	88-62	CTCCAATGCACCCAAGACAGCAGAAAG	9
	H-Y4	88-62	CTCCAATGCACCCAAGACAGCAGAAAG	9
25	H-Y5	88-62	CTCCAATGCACCCAAGACAGCAGAAAG	9
	H-Y6	88-62	CTCCAATGCACCCAAGACAGCAGAAAG	9
	H-Y7	88-62	CTCCAATGCACCCAAGACAGCAGAAAG	9
	H-Y8	88-62	CTCCAATGCACCCAAGACAGCAGAAAG	9
	H-Y9	88-62	CTCCAATGCACCCAAGACAGCAGAAAG	9
30	H-Y10	88-62	CTCCAATGCACCCAAGACAGCAGAAAG	9
	H-Za1	89-62	GCTCCAATGCACCCAAGACAGCAGAAAG	10
	H-Za2	89-62	GCTCCAATGCACCCAAGACAGCAGAAAG	10
	H-Za3	89-62	GCTCCAATGCACCCAAGACAGCAGAAAG	10
	H-Za4	89-62	GCTCCAATGCACCCAAGACAGCAGAAAG	10
35	H-Za5	89-62	GCTCCAATGCACCCAAGACAGCAGAAAG	10
	H-Za6	89-62	GCTCCAATGCACCCAAGACAGCAGAAAG	10
	H-Za7	89-62	GCTCCAATGCACCCAAGACAGCAGAAAG	10
	H-Za8	89-62	GCTCCAATGCACCCAAGACAGCAGAAAG	10
	H-Za9	89-62	GCTCCAATGCACCCAAGACAGCAGAAAG	10
40	H-Za10	89-62	GCTCCAATGCACCCAAGACAGCAGAAAG	10
	H-Z1	90-62	GGCTCCAATGCACCCAAGACAGCAGAAAG	11
	H-Z2	90-62	GGCTCCAATGCACCCAAGACAGCAGAAAG	11
	H-Z3	90-62	GGCTCCAATGCACCCAAGACAGCAGAAAG	11
	H-Z4	90-62	GGCTCCAATGCACCCAAGACAGCAGAAAG	11
45	H-Z5	90-62	GGCTCCAATGCACCCAAGACAGCAGAAAG	11
	H-Z6	90-62	GGCTCCAATGCACCCAAGACAGCAGAAAG	11
	H-Z7	90-62	GGCTCCAATGCACCCAAGACAGCAGAAAG	11
	H-Z8	90-62	GGCTCCAATGCACCCAAGACAGCAGAAAG	11
	H-Z9	90-62	GGCTCCAATGCACCCAAGACAGCAGAAAG	11
50	H-Z10	90-62	GGCTCCAATGCACCCAAGACAGCAGAAAG	11

TABLE 1 (conti'.)

	OLIGO	TARGETED SITE	SEQUENCE (5' → 3')	SEQ ID NO:
5	H-3D1	80-63	CACCCAAGACAGCAGAAA	12
	H-3D2	80-63	CACCCAAGACAGCAGAAA	12
	H-3D3	80-63	CACCCAAGACAGCAGAAA	12
	H-3D4	80-63	CACCCAAGACAGCAGAAA	12
10	H-3D5	80-63	CACCCAAGACAGCAGAAA	12
	H-3D6	80-63	CACCCAAGACAGCAGAAA	12
	H-3D7	80-63	CACCCAAGACAGCAGAAA	12
	H-3D8	80-63	CACCCAAGACAGCAGAAA	12
	H-3D9	80-63	CACCCAAGACAGCAGAAA	12
15	H-3D10	80-63	CACCCAAGACAGCAGAAA	12
	H-3E1	80-64	CACCCAAGACAGCAGAA	13
	H-3E2	80-64	CACCCAAGACAGCAGAA	13
	H-3E3	80-64	CACCCAAGACAGCAGAA	13
	H-3E4	80-64	CACCCAAGACAGCAGAA	13
20	H-3E5	80-64	CACCCAAGACAGCAGAA	13
	H-3E6	80-64	CACCCAAGACAGCAGAA	13
	H-3E7	80-64	CACCCAAGACAGCAGAA	13
	H-3E8	80-64	CACCCAAGACAGCAGAA	13
	H-3E9	80-64	CACCCAAGACAGCAGAA	13
25	H-3E10	80-64	CACCCAAGACAGCAGAA	13
	H-3F1	80-65	CACCCAAGACAGCAGA	14
	H-3F2	80-65	CACCCAAGACAGCAGA	14
	H-3F3	80-65	CACCCAAGACAGCAGA	14
	H-3F4	80-65	CACCCAAGACAGCAGA	14
30	H-3F5	80-65	CACCCAAGACAGCAGA	14
	H-3F6	80-65	CACCCAAGACAGCAGA	14
	H-3F7	80-65	CACCCAAGACAGCAGA	14
	H-3F8	80-65	CACCCAAGACAGCAGA	14
	H-3F9	80-65	CACCCAAGACAGCAGA	14
35	H-3F10	80-65	CACCCAAGACAGCAGA	14
	H-3G1	80-60	CACCCAAGACAGCAGAAAGTT	15
	H-3G2	80-60	CACCCAAGACAGCAGAAAGTT	15
	H-3G3	80-60	CACCCAAGACAGCAGAAAGTT	15
	H-3G4	80-60	CACCCAAGACAGCAGAAAGTT	15
40	H-3G5	80-60	CACCCAAGACAGCAGAAAGTT	15
	H-3G6	80-60	CACCCAAGACAGCAGAAAGTT	15
	H-3G7	80-60	CACCCAAGACAGCAGAAAGTT	15
	H-3G8	80-60	CACCCAAGACAGCAGAAAGTT	15
	H-3G9	80-60	CACCCAAGACAGCAGAAAGTT	15
45	H-3G10	80-60	CACCCAAGACAGCAGAAAGTT	15
	H-3H1	80-58	CACCCAAGACAGCAGAAAGTTTCAT	16
	H-3H2	80-58	CACCCAAGACAGCAGAAAGTTTCAT	16
	H-3H3	80-58	CACCCAAGACAGCAGAAAGTTTCAT	16
	H-3H4	80-58	CACCCAAGACAGCAGAAAGTTTCAT	16
50	H-3H5	80-58	CACCCAAGACAGCAGAAAGTTTCAT	16

TABLE 1 (conti'.)

	OLIGO	TARGETED SITE	SEQUENCE (5' → 3')	SEQ ID NO:
5	H-3H6	80-58	CACCCAAGACAGCAGAAAGT TCAT	16
	H-3H7	80-58	CACCCAAGACAGCAGAAAGTTCAT	16
	H-3H8	80-58	CACCCAAGACAGCAGAAAGTTCAT	16
	H-3H9	80-58	CACCCAAGACAGCAGAAAGTTCAT	16
10	H-3H10	80-58	CACCCAAGACAGCAGAAAGTTCAT	16

Preferably, the nucleotides bolded in the
 15 oligonucleotides above are 2'-O-alkylated, and all
 of the nucleotides are linked via non-
 phosphodiester internucleotide linkages such as
 phosphorothioates.

20 The preparation of these modified
 oligonucleotides is well known in the art
 (reviewed in Agrawal (1992) *Trends Biotechnol.* **10**:152-
 158; Agrawal et al. (1995) *Curr. Opin. Biotechnol.* **6**:12-
 19). For example, nucleotides can be covalently
 25 linked using art-recognized techniques such as
 phosphoramidate, H-phosphonate chemistry, or
 methylphosphoramidate chemistry (see, e.g., Uhlmann et
 al. (1990) *Chem. Rev.* **90**:543-584; Agrawal et al.
 (1987) *Tetrahedron. Lett.* **28**: (31):3539-3542); Caruthers
 30 et al. (1987) *Meth. Enzymol.* **154**:287-313; U.S. Patent
 5,149,798). Oligomeric phosphorothioate analogs
 can be prepared using methods well known in the
 field such as methoxyphosphoramidite (see, e.g.,
 Agrawal et al. (1988) *Proc. Natl. Acad. Sci. (USA)*
 35 **85**:7079-7083) or H-phosphonate (see, e.g., Froehler
 (1986) *Tetrahedron Lett.* **27**:5575-5578) chemistry. The

synthetic methods described in Bergot et al. (*J. Chromatog.* (1992) **559**:35-42) can also be used.

5 The synthetic antisense oligonucleotides of
the invention in the form of a therapeutic
formulation are useful in treating diseases, and
disorders, and conditions associated with
angiogenesis and neovascularization including, but
not limited to, retinal neovascularization, tumor
10 growth, and wound healing. In such methods, a
therapeutic amount of a synthetic oligonucleotide
of the invention and effective in inhibiting the
expression of vascular endothelial growth factor
is administered to a cell. This cell may be part
15 of a cell culture, a neovascularized tissue
culture, or may be part or the whole body of an
animal such as a human or other mammal.
Administration may be bolus, intermittent, or
continuous, depending on the condition and
20 response, as determined by those with skill in the
art. In some preferred embodiments of the methods
of the invention described above, the
oligonucleotide is administered locally (e.g.,
intraocularly or interlesionally) and/or
25 systemically. The term "local administration"
refers to delivery to a defined area or region of
the body, while the term "systemic administration"
is meant to encompass delivery to the whole
organism by oral ingestion, or by intramuscular,
30 intravenous, subcutaneous, or intraperitoneal
injection.

Such methods can be used to treat retinopathy
of prematurity (ROP), diabetic retinopathy, age-

related macular degeneration, sickle cell retinopathy, neovascular glaucoma, retinal vein occlusion, and other hypoxic diseases.

5 The synthetic oligonucleotides of the invention may be used as part of a pharmaceutical composition when combined with a physiologically and/or pharmaceutically acceptable carrier. The characteristics of the carrier will depend on the
10 route of administration. Such a composition may contain, in addition to the synthetic oligonucleotide and carrier, diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The
15 pharmaceutical composition of the invention may also contain other active factors and/or agents which enhance inhibition of VEGF expression or which will reduce neovascularization. For example, combinations of synthetic
20 oligonucleotides, each of which is directed to different regions of the VEGF mRNA, may be used in the pharmaceutical compositions of the invention. The pharmaceutical composition of the invention may further contain nucleotide analogs such as
25 azidothymidine, dideoxycytidine, dideoxyinosine, and the like. Such additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic effect with the synthetic oligonucleotide of the invention, or
30 to minimize side-effects caused by the synthetic oligonucleotide of the invention. Conversely, the synthetic oligonucleotide of the invention may be included in formulations of a particular anti-VEGF or anti-neovascularization factor and/or agent to

minimize side effects of the anti-VEGF factor and/or agent.

5 The pharmaceutical composition of the invention may be in the form of a liposome in which the synthetic oligonucleotides of the invention is combined, in addition to other pharmaceutically acceptable carriers, with
10 amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers which are in aqueous solution. Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides,
15 lysolecithin, phospholipids, saponin, bile acids, and the like. One particularly useful lipid carrier is lipofectin. Preparation of such liposomal formulations is within the level of skill in the art, as disclosed, for example, in
20 U.S. Patent No. 4,235,871; U.S. Patent No. 4,501,728; U.S. Patent No. 4,837,028; and U.S. Patent No. 4,737,323. The pharmaceutical composition of the invention may further include compounds such as cyclodextrins and the like which
25 enhance delivery of oligonucleotides into cells, as described by Zhao et al. (in press), or slow release polymers.

30 As used herein, the term "therapeutically effective amount" means the total amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, i.e., healing of chronic conditions characterized by neovascularization or

a reduction in neovascularization, itself, or in an increase in rate of healing of such conditions. When applied to an individual active ingredient, administered alone, the term refers to that
5 ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.

10

In practicing the method of treatment or use of the present invention, a therapeutically effective amount of one, two, or more of the synthetic oligonucleotides of the invention is
15 administered to a subject afflicted with a disease or disorder related to neovascularization, or to a tissue which has been neovascularized. The synthetic oligonucleotide of the invention may be administered in accordance with the method of the
20 invention either alone or in combination with other known therapies for neovascularization. When co-administered with one or more other therapies, the synthetic oligonucleotide of the invention may be administered either
25 simultaneously with the other treatment(s), or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering the synthetic oligonucleotide of the invention in combination
30 with the other therapy.

Administration of the synthetic oligonucleotide of the invention used in the pharmaceutical composition or to practice the

method of the present invention can be carried out
in a variety of conventional ways, such as
intraocular, oral ingestion, inhalation, or
cutaneous, subcutaneous, intramuscular, or
5 intravenous injection.

When a therapeutically effective amount of
synthetic oligonucleotide of the invention is
administered orally, the synthetic oligonucleotide
10 will be in the form of a tablet, capsule, powder,
solution or elixir. When administered in tablet
form, the pharmaceutical composition of the
invention may additionally contain a solid carrier
such as a gelatin or an adjuvant. The tablet,
15 capsule, and powder contain from about 5 to 95%
synthetic oligonucleotide and preferably from
about 25 to 90% synthetic oligonucleotide. When
administered in liquid form, a liquid carrier such
as water, petroleum, oils of animal or plant
20 origin such as peanut oil, mineral oil, soybean
oil, sesame oil, or synthetic oils may be added.
The liquid form of the pharmaceutical composition
may further contain physiological saline solution,
dextrose or other saccharide solution, or glycols
25 such as ethylene glycol, propylene glycol or
polyethylene glycol. When administered in liquid
form, the pharmaceutical composition contains from
about 0.5 to 90% by weight of the synthetic
oligonucleotide and preferably from about 1 to 50%
30 synthetic oligonucleotide.

When a therapeutically effective amount of
synthetic oligonucleotide of the invention is
administered by intravenous, subcutaneous,

intramuscular, intraocular, or intraperitoneal injection, the synthetic oligonucleotide will be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the art. A preferred pharmaceutical composition for intravenous, subcutaneous, intramuscular, intraperitoneal, or intraocular injection should contain, in addition to the synthetic oligonucleotide, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art. The pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art.

The amount of synthetic oligonucleotide in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone. Ultimately, the attending physician will decide the amount of synthetic oligonucleotide with which to treat each individual patient. Initially, the attending physician will administer low doses of the synthetic oligonucleotide and observe the patient's response. Larger doses of synthetic oligonucleotide may be administered until the optimal therapeutic effect is obtained for the

patient, and at that point the dosage is not increased further. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention
5 should contain about 10 μ g to about 20 mg of synthetic oligonucleotide per kg body or organ weight.

The duration of intravenous therapy using the pharmaceutical composition of the present
10 invention will vary, depending on the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient. Ultimately the attending
15 physician will decide on the appropriate duration of intravenous therapy using the pharmaceutical composition of the present invention.

Some diseases lend themselves to acute
20 treatment while others require to longer term therapy. Proliferative retinopathy can reach a threshold in a matter of days as seen in ROP, some cases of diabetic retinopathy, and neovascular glaucoma. Premature infants are at risk for
25 neovascularization around what would be 35 weeks gestation, a few weeks after birth, and will remain at risk for a short period of time until the retina becomes vascularized. Diabetic retinopathy can be acute but may also smolder in
30 the proliferative phase for considerably longer. Diabetic retinopathy will eventually become quiescent as the vasoproliferative signal diminishes with neovascularization or destruction of the retina.

Both acute and long term intervention in retinal disease are worthy goals. Intravitreal injections of oligonucleotides against VEGF can be an effective means of inhibiting retinal
5 neovascularization in an acute situation. However for long term therapy over a period of years, systemic delivery (intraperitoneal, intramuscular, subcutaneous, intravenous) either with carriers such as saline, slow release polymers, or
10 liposomes should be considered.

In some cases of chronic neovascular disease, systemic administration of oligonucleotides may be preferable. Since the disease process concerns
15 vessels which are abnormal and leaky, the problem of passage through the blood brain barrier may not be a problem. Therefore, systemic delivery may prove efficacious. The frequency of injections is from continuous infusion to once a month,
20 depending on the disease process and the biological half life of the oligonucleotides.

In addition to inhibiting neovascularization *in vivo*, antisense oligonucleotides specific for
25 VEGF are useful in determining the role of this cytokine in processes where neovascularization is involved. For example, this technology is useful in *in vitro* systems which mimic blood vessel formation and permeability, and in *in vivo* system
30 models of neovascularization, such as the murine model described below.

A murine model of oxygen-induced retinal neovascularization has been established which

occurs in 100% of treated animals and is quantifiable (Smith et al. (1994) *Invest. Ophthalmol. Vis. Sci.* **35**:101-111). Using this model, a correlation has been determined between increasing
5 expression of VEGF message and the onset of retinal neovascularization in the inner nuclear and ganglion cell layers (i.e., in Müller cells) (Pierce et al. (1995) *Proc. Natl. Acad. Sci. (USA)* (in press)). This result has been confirmed by
10 Northern blot and *in situ* hybridization analysis of whole retinas at different time points during the development of neovascularization (Pierce et al., *ibid.*).

15 Oligonucleotides of the invention are also useful in a method of reducing the expression of VEGF. The target VEGF expression can be *in vitro* or in any cell which expresses VEGF. In this method, nucleic acid specific for VEGF is
20 contacted with an oligonucleotide of the invention such that transcription of the nucleic acid to mRNA and/or protein is reduced or inhibited.

25 That oligonucleotides of the invention can inhibit VEGF expression at the protein level can be demonstrated using an ELISA which specifically detects human VEGF and a VEGF-expressing cell line such as a human glioblastoma (e.g., U373 ATCC Ac. no. HTB17, American Type Culture Collection,
30 Rockville, MD) or a human melanoma (e.g., SK-MEL-2, ATCC Ac. no. HTB68, American Type Culture Collection, Rockville, MD; or M21). Briefly, when a human glioblastoma cell line U373 and a human

melanoma cell line M21 were treated with VEGF-specific oligonucleotides of the invention, these cells stop expressing VEGF in a sequence-specific manner, as shown in FIGS. 2, 3, and 4, and in FIG. 5, respectively. FIG. 6 demonstrates that modification of the oligonucleotides does not reduce their inhibitory activity. Oligonucleotides of the invention also reduced VEGF mRNA expression, as demonstrated by the Northern analyses described in EXAMPLE 4 below.

VEGF's role in tumor formation *in vivo* can be demonstrated using an athymic mouse injected with as an animal model. M21 cells are known to generate palpable tumors in mice in about 1 to 1.5 weeks. Alternately, a U373 cell line which has been passed through an athymic mouse in the presence of Engelbreth Holm Swarm (EMS) tumor matrix (Matrigel™, Collaborative Research, Waltham, MA) may be used. When mice are injected with VEGF-specific oligonucleotides of the invention, there will be a reduction in tumor weight and volume if VEGF expression is reduced by oligonucleotides or pharmaceutical formulations of the invention.

That VEGF plays a role in retinal neovascularization has been shown using the murine model of neovascularization described above. Three independent experiments were performed using antisense oligonucleotides specific for VEGF (JG-3 (SEQ ID NO:17), JG-4, (SEQ ID NO:18), and Vm (SEQ ID NO:19), and a corresponding sense oligonucleotide (V2 (SEQ ID NO:20)). These

oligonucleotides were designed using the known nucleic sequence of murine VEGF (Claffee et al. (1992) *J. Biol. Chem.* **267**:16317-16322). The sequence of the Vm oligonucleotide is targeted to the sequence surrounding the translational TGA stop site (TGA). The sequence of JG-4 is targeted to the sequence 5' to and containing the ATG of the translational start site of the murine VEGF molecule. The sequence of JG-3 is targeted to the 5' untranslated region, and the V2 sense sequence is targeted to the sequence surrounding the translational start site (ATG).

The following examples illustrate the preferred modes of making and practicing the present invention, but are not meant to limit the scope of the invention since alternative methods may be utilized to obtain similar results.

EXAMPLE 1 PREPARATION OF VEGF-SPECIFIC OLIGONUCLEOTIDES

Human VEGF cDNA is transcribed *in vitro* using an *in vitro* eucaryotic transcription kit (Stratagene, La Jolla, CA). The RNA is labelled with ³²P using T-4 polynucleotide kinase as described by (Sambrook et al. (1989) *Molecular Cloning; a Laboratory Manual*, Cold Spring Harbor Laboratory Press, NY, Vol. 1, pp. 5.71). The labelled RNA is incubated in the presence of a randomer 20mer library and RNase H, an enzyme which cleaves RNA-DNA duplexes (Boehringer Mannheim, Indianapolis, IN). Cleavage patterns are analyzed on a 6% polyacrylamide urea gel. The specific location of the cleaved

fragments is determined using a human VEGF sequence ladder (Sequenase Kit, United States Biochemical, Cleveland, OH).

5 Oligonucleotides having sequences
complementary to VEGF nucleic acid determined as
described above were synthesized on a Pharmacia
Gene Assembler series synthesizer using the
phosphoramidite procedure (see, e.g., Uhlmann et
10 al. (*Chem. Rev.* (1990) **90**:534-583; Agrawal (1992)
Trends in Biotech. **10**:152-158; Agrawal et al. (1995)
Curr. Opin. Biotechnol. **6**:12-19). Following assembly and
deprotection, oligonucleotides were ethanol
precipitated twice, dried, and suspended in
15 phosphate-buffered saline (PBS) at the desired
concentration.

The purity of these oligonucleotides was tested by capillary gel electrophoreses and ion exchange HPLC. Endotoxin levels in the oligonucleotide preparation was determined using the Luminous Amebocyte Assay (Bang (1953) *Biol. Bull.* (Woods Hole, MA) **105**:361-362).

25 EXAMPLE 2
HUMAN CELL CULTURE

U373 human glioblastoma cells (American Type Culture Collection, Rockville, MD, ATCC Ac. no. HTB17) were cultured in Dulbecco's modified Earls (DME) medium containing glucose (4500 mg/ml) and 2 mM glutamate (Mediatech, Washington, DC) supplemented with penicillin/streptomycin (100 IU/MI/100 mcg/ml, Mediatech, Washington, DC). The

cells were cultured at 37°C under 10% CO₂. The cells were plated in 96 well tissue culture dishes (Costar Corp., Cambridge, MA) and maintained as above. The cells were placed under anoxic
5 conditions for 18-20 hours using an anaerobic chamber (BBL Gas Pak, Cockeysville, MD) or in the presence of 250 μ M CoCl₂.

EXAMPLE 3 ELISA VEGF PROTEIN STUDY

10

U373 glioblastoma cells were plated in a 96 well tissue culture dish and treated overnight with varying concentrations of antisense
15 oligonucleotides against human VEGF in the presence of 5 μ g/ml lipofectin. The cells were refed after 7 to 12 hours with fresh media and allowed to recover for 5 to 7 hours. The dishes were placed under hypoxic conditions for 18 to 20
20 hours using an anaerobic chamber (Gas Pac, Cockeysville, MD) or in the presence of 250 μ M CoCl₂. Cells maintained under normoxic conditions served as uninduced controls. The media was analyzed using the antigen capture ELISA assay
25 described below (approximately 24 hours post treatment).

The culture medium from the cells described in EXAMPLE 2 was analyzed for VEGF protein as
30 follows. 96-well plates (Maxisorb ELISA Nunc A/S, Camstrup, Denmark) were treated overnight at 4°C with 100 μ l/well of the capture antibody, a monoclonal antibody against human VEGF (R&D Systems, Minneapolis, MN, 2.5 μ g/ml in 1X PBS).
35 The wells were washed three times with 1x

PBS/0.05% Tween-20 (United States Biochemical, Cleveland, OH) using a plate washer (Dynatech, Gurnsey Channel Islands). Non-specific binding sites in the wells were blocked by adding 2% normal human serum (200 μ l) and incubating the plate at 37°C for 2 hours. This blocking solution was removed and 200 μ l conditioned medium containing human VEGF added to each well and incubated at 37°C for 2 to 3 hours or overnight at 4°C. The plates were washed as described above. 100 μ l of the primary antibody (618/619, 2 μ g/ml in normal human serum) was added to each well and incubated at 37°C for 1 to 2 hours. The primary antibody was an affinity purified rabbit anti-human VEGF polyclonal). The plates were washed as described above. 100 μ l of the detection antibody, a horse radish peroxidase-labelled goat anti-rabbit IgG monoclonal antibody (1:10,000, Vector Laboratories, Burlingame, CA), was added to each well and incubated at 37°C for 1 hour. The plates were washed as described above. The wells were developed using the TMB microwell peroxidase developing system (Kirkegaard and Perry, Gaithersburg, MD), and quantified at 450 nm using a Ceres 900 plate reader (Bio-Tek Instruments, Inc., Winooski, Vermont). The linear range of this assay is between 2 ng and 0.01 ng human VEGF. Representative results are shown in FIGS. 2-6.

EXAMPLE 4 NORTHERN BLOTTING

In order to determine the level at which inhibition of VEGF expression occurs in cells in

the presence of an oligonucleotide of the invention, Northern blotting was carried out. Human U373 cells cultured as described in EXAMPLE 2 above were plated in 100 mm tissue culture dishes and treated for 12 hours in the presence of 5 μ g/ml lipofectin (Gibco-BRL, Gaithersburg, MD) as a lipid carrier with oligonucleotide H-3 (SEQ ID NO:1) and sense control (SEQ ID NO:21) at 0.05 μ M, 0.5 μ M, and 2.0 μ M, respectively. The cells were refed after 7 to 8 hours with fresh media. The cells were placed in hypoxia for 18 to 20 hours or in the presence of 250 μ M CoCl₂, and total RNA was isolated using Trizol™ (Gibco-BRL, Gaithersburg, MD) and the single-step acid guanidinium thiocyanate-phenol-chloroform extraction method described by Chomczynski et al. (*Anal. Biochem.* (1987) **162**:156-159). Northern blotting was performed according to the methods of Sambrook et al. (*Molecular Cloning: a Laboratory Manual*, Cold Spring Harbor Laboratory Press, NY) (1989) Vol. 1, pp. 7.38) or Arcellana-Panlilio et al. (*Meth. Enz.* (1993) **225**:303-328). All RNA signals were quantified on a Phosphorimager (BioRad, Hercules, CA) and normalized using the 36B4 cDNA probe (Laborda (1991) *Nucleic Acids Res.* **19**:3998). RNA expression was reduced in the presence of VEGF-specific oligonucleotides of the invention, and is not significantly affected by the presence of control sense oligonucleotide.

30

EXAMPLE 5 IN VIVO STUDIES

A. Matrigel Studies

5

U373 glioblastoma cells were treated with 0.5 μ M antisense phosphorothioate oligodeoxynucleotide (H-3, SEQ ID NO:1) or control (H3-sense phosphorothioate oligonucleotide; SEQ ID NO:21) for 7 hours in the presence of 5 μ g/ μ l Lipofectin (Gibco-BRL, Gaithersburg, MD). 1 x 10⁶ oligonucleotide-treated cells were mixed with 250 μ l Matrigel[™] (Collaborative Research, Waltham, MA; 10-12 mg/ml) and injected subcutaneously into 6-8 week old athymic mice (about 20 g) (Charles River Laboratories, Wilmington, MA) on both the left and right sides. These cells respond to hypoxia and express increased levels of VEGF. The mice were maintained *ad libitum* and sacrificed 8 days post injection. The skin was dissected to expose the Matrigel pellet. Gross photography of the surrounding blood vessels was performed with a Zeiss Macroscopic. The Matrigel plugs were removed and fixed in formalin for paraffin embedding and histological analysis. Tissue sections were stained with hematoxylin and eosin for quantitation of blood vessel growth into the Matrigel plug.

The injection of Matrigel alone resulted in a clear plug with no apparent angiogenesis. Matrigel plugs combined with U373 glioblastoma cells contained visible hemorrhaging. In addition, the capillary bed surrounding the plug was more dense and the blood vessels were more

35

tortuous. Athymic mice injected with Matrigel plugs combined with antisense oligonucleotide-treated cells generated less angiogenesis than the mice injected with Matrigel plugs and either
5 untreated cells or cells pretreated with the control oligonucleotide. Matrigel plugs containing antisense treated cells also had less visible hemorrhaging. The results suggest that antisense oligonucleotide treatment inhibit VEGF-
10 induced angiogenesis.

B. Tumor Studies

6 week old athymic mice (about 20 g) are
15 purchased from Charles River Laboratories. Human melanoma M21 cells or human glioblastoma U373 cells which have been passaged through athymic mice in the presence of Matrigel are injected subcutaneously ($2-20 \times 10^6$) into the flank of
20 athymic mice. Palpable tumors are generated in 1-2 weeks. Subcutaneous antisense or sense control oligonucleotide injections begin one day following the injection of the tumor cells. The concentration of oligonucleotide is determined and
25 ranges between 5 and 50 mg/kg. Animals are then injected over a period of three weeks. They are then sacrificed and the tumors removed. Tumors are analyzed initially for weight and volume. In addition, analysis includes sectioning and
30 staining for VEGF/VPF protein using an anti- human VEGF/VPF monoclonal antibody (R&D Systems, Minneapolis, MN) or VEGF/VPF RNA using *in situ* hybridization techniques. Mice injected with antisense oligonucleotides of the invention are

expected to have smaller tumors than those injected with vehicle or the control.

EXAMPLE 6

5 ANIMAL MODEL OF RETINAL NEOVASCULARIZATION

A. Preparation of Oligonucleotides

10 Synthesis of the following oligonucleotides: JG-3 (SEQ ID NO:17), JG-4 (SEQ ID NO:18), Vm (SEQ ID NO:19), and V2 (SEQ ID NO:20), was performed as described in Example 1.

15 B. Preparation of Animal Model

Seven day postnatal mice (P7, C57b1/6J, (Children's Hospital Breeding Facilities, Boston, MA) were exposed to 5 days of hyperoxic conditions (75 +/- 2%) oxygen in a sealed incubator connected to a Bird 3-M oxygen blender (flow rate: 1.5 liters/minute; Bird, Palm Springs, CA). The oxygen concentration was monitored by means of an oxygen analyzer (Beckman, Model D2, Irvine, CA).
20 After 5 days (P12), the mice were returned to room air. Maximal retinal neovascularization was observed 5 days after return to room air (P17). After P21, the level of retinal neovascularization was just beginning to regress.

30

C. Treatment

After mice had been removed from oxygen, antisense oligonucleotides were injected into the vitreous with a Hamilton syringe and a 33 gauge
35 needle (Hamilton Company, Reno, NV). The animals

were anesthetized for the procedure with Avertin ip. The mice were given a single injection of antisense oligonucleotides (or sense or non-sense controls) at P12 achieving a final concentration of approximately 30-50 μ M. The animals were sacrificed at P17 with tribromoethanol ip (0.1 ml/g body weight) and cervical dislocation.

D. Microscopy

The eyes were enucleated, fixed in 4% paraformaldehyde, and embedded in paraffin. Serial sections of the whole eyes were cut sagittally, through the cornea, and parallel to the optic nerve. The sections were stained with hematoxylin and periodic acid-Schiff (PAS) stain. The extent of neovascularization in the treated eyes was determined by counting endothelial cell nuclei extending past the internal limiting membrane into the vitreous. Nuclei from new vessels and vessel profiles could be distinguished from other structures in the retina and counted in cross-section with light microscopy. Additional eyes were sectioned and examined by *in situ* hybridization to a VEGF probe.

To examine the retinal vasculature using fluorescein-dextran, the mice were perfused with a 50 mg/ml solution of high molecular weight fluorescein-dextran (Sigma Chemical Company, St. Louis, MO) in 4% paraformaldehyde. The eyes were enucleated, fixed in paraformaldehyde, and flat-mounted with glycerol-gelatin. The flat-mounted retinas were viewed and photographed by

fluorescence microscopy using an Olympus BX60
fluorescence microscope (Olympus America Corp.,
Bellingham, MA).

5 EQUIVALENTS

Those skilled in the art will recognize, or
be able to ascertain, using no more than routine
experimentation, numerous equivalents to the
10 specific substances and procedures described
herein. Such equivalents are considered to be
within the scope of this invention, and are
covered by the following claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Robinson, Gregory S.
- (ii) TITLE OF INVENTION: MODIFIED VEGF OLIGONUCLEOTIDES
- (iii) NUMBER OF SEQUENCES: 21
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Lappin & Kusmer
 - (B) STREET: 200 State Street
 - (C) CITY: Boston
 - (D) STATE: MA
 - (E) COUNTRY: USA
 - (F) ZIP: 02109
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: US
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Kerner, Ann-Louise
 - (B) REGISTRATION NUMBER: 33,523
 - (C) REFERENCE/DOCKET NUMBER: HYZ-031CP2
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 617-330-1300
 - (B) TELEFAX: 617-330-1311

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 19 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CACCCAAGAC AGCAGAAAG

19

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA/RNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

GCACCCAAGA CAGCAGAAAG

20

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA/RNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

TGCACCCAAG ACAGCAGAAA G

21

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA/RNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

ATGCACCCAA GACAGCAGAA AG

22

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 23 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA/RNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

AATGCACCCA AGACAGCAGA AAG

23

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 24 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA/RNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

CAATGCACCC AAGACAGCAG AAAG

24

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 25 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA/RNA
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: YES
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:
CCAATGCACC CAAGACAGCA GAAAG 25

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 26 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA/RNA
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: YES
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:
TCCAATGCAC CCAAGACAGC AGAAAG 26

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 27 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA/RNA
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: YES
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:
CTCCAATGCA CCAAGACAG CAGAAAG 27

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 28 base pairs
 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA/RNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

GCTCCAATGC ACCCAAGACA GCAGAAAG

28

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA/RNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

GGCTCCAATG CACCCAAGAC AGCAGAAAG

29

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA/RNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

CACCCAAGAC AGCAGAAA

18

(2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 17 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA/RNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

CACCCAAGAC AGCAGAA

17

(2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 16 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA/RNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

CACCCAAGAC AGCAGA

16

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 21 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA/RNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

CACCCAAGAC AGCAGAAAGT T

21

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA/RNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

CACCCAAGAC AGCAGAAAGT TCAT

24

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

TCGCGCTCCC TCTCTCCGGC

20

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

CATGGTTTCG GAGGGCGTC

19

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 21 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

CAGCCTGGCT CACCGCCTTG G

21

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 21 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

TCCGAAACCA TGAACCTTCT G

21

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 19 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

CTTTCTGCTG TCTTGGGTG

19

What is claimed is:

1. A synthetic oligonucleotide complementary to
a nucleic acid specific for human vascular
5 endothelial growth factor selected from the group
consisting of an oligonucleotide having SEQ ID
NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ
ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9,
SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID
10 NO:13, SEQ ID NO:14, SEQ ID NO:15, and SEQ ID
NO:16.
2. The oligonucleotide of claim 1 having SEQ ID
NO:2.
15
3. The oligonucleotide of claim 1 having SEQ ID
NO:3.
4. The oligonucleotide of claim 1 having SEQ ID
20 NO:4.
5. The oligonucleotide of claim 1 having SEQ ID
NO:5.
- 25 6. The oligonucleotide of claim 1 having SEQ ID
NO:6.
7. The oligonucleotide of claim 1 having SEQ ID
NO:7.
30
8. The oligonucleotide of claim 1 having SEQ ID
NO:8.

9. The oligonucleotide of claim 1 having SEQ ID NO:9.
10. The oligonucleotide of claim 1 having SEQ ID NO:10.
11. The oligonucleotide of claim 1 having SEQ ID NO:11.
12. The oligonucleotide of claim 1 having SEQ ID NO:12.
13. The oligonucleotide of claim 1 having SEQ ID NO:13.
14. The oligonucleotide of claim 1 having SEQ ID NO:14.
15. The oligonucleotide of claim 1 having SEQ ID NO:15.
16. The oligonucleotide of claim 1 having SEQ ID NO:16.
17. The oligonucleotide of claim 1 having a modification selected from the group consisting of an alkylphosphonate, phosphorothioate, phosphorodithioate, phosphate ester, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetamdate, and carboxymethyl ester internucleotide linkage, and a combination thereof.

18. The oligonucleotide of claim 17 having at least one phosphorothioate internucleotide linkage.
- 5 19. The oligonucleotide of claim 18 having phosphorothioate internucleotide linkages.
20. The oligonucleotide of claim 1 consisting essentially of 2'-O-alkylated ribonucleotides.
- 10 21. The oligonucleotide of claim 1 comprising four or five 5' 2'-O-alkylated ribonucleotides.
22. The oligonucleotide of claim 1 comprising
15 four or five 3' 2'-O-alkylated ribonucleotides.
23. The oligonucleotide of claim 21 comprising four or five 3' 2'-O-alkylated ribonucleotides.
- 20 24. The oligonucleotide of claim 18 comprising four or five 5' 2'-O-alkylated ribonucleotides.
25. A method of inhibiting VEGF expression comprising the step of contacting nucleic acid
25 specific for VEGF with an oligonucleotide of claim 1.
26. A method of inhibiting VEGF expression comprising the step of contacting nucleic acid
30 specific for VEGF with an oligonucleotide of claim 17.

27. A pharmaceutical composition comprising at least one synthetic oligonucleotide of claim 1 in a physiologically acceptable carrier.
- 5 28. A pharmaceutical composition comprising at least one synthetic oligonucleotide of claim 17 in a physiologically acceptable carrier.

1/6




FIG. 1

2/6




FIG. 2

3/6




FIG. 3

4/6




FIG. 4

SUBSTITUTE SHEET (RULE 26)

5/6




FIG. 5

6/6




FIG. 6

SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/19320

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/11 A61K31/70 C07H21/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12N C07H A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 04142 A (HYBRIDON INC ; ROBINSON GREGORY S (US)) 9 February 1995	1,15-28
Y	see the whole document	1-28
O,Y	<p>--- ANTISENSE RES.DEV. 5 (SPRING 95);87-8;OP-10, XP002006442 UCHIDA, K. ET AL.: "Selection of antisense oligodeoxyribonucleotides that inhibit VEGF/VPF expression in a cell-free system" cited in the application see abstract & 1ST INTERNATIONAL ANTISENSE CONFERENCE IN JAPAN, 4 - 7 December 1994, ---</p> <p style="text-align: center;">-/--</p>	1-16,25,27

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

8 April 1997

Date of mailing of the international search report

16. 04. 97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Andres, S

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/19320

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 268, no. 19, 5 July 1993, pages 14514-14522, XP000576145 MONIA B P ET AL: "EVALUATION OF 2'-MODIFIED OLIGONUCLEOTIDES CONTAINING 2'-DEOXY GAPS AS ANTISENSE INHIBITORS OF GENE EXPRESSION" see the whole document ---	17-24, 26,28
A	CHEMICAL REVIEWS, vol. 90, no. 4, 1 June 1990, pages 543-584, XP000141412 UHLMANN E ET AL: "ANTISENSE OLIGONUCLEOTIDES: A NEW THERAPEUTIC PRINCIPLE" cited in the application ---	
A	JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 266, 25 June 1991, MD US, pages 11947-11954, XP002007151 TISCHER, E. ET AL.: "The human gene for vascular endothelial growth factor" cited in the application ---	
A	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 193, 15 June 1993, ORLANDO, FL US, pages 631-638, XP002007152 ADAMIS, A. ET AL.: "Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells" cited in the application ---	
P,X	WO 96 27006 A (HYBRIDON INC) 6 September 1996 see SEQ IDs 55 to 69 see claims 28-51,78,79,106,107 ---	1-28
P,X	WO 96 23065 A (HYBRIDON INC ;CHILDRENS MEDICAL CENTER (US)) 1 August 1996 see the whole document -----	1-14, 17-28

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 96/ 19320

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 25,26
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although these claims (as far as in vivo methods are concerned) are directed to a method of treatment of (diagnostic method practised on) the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 96/19320

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9504142 A	09-02-95	AU 7516894 A	28-02-95
		CA 2167680 A	09-02-95
		CN 1131437 A	18-09-96
		EP 0711343 A	15-05-96
		FI 960374 A	25-03-96
		NO 960303 A	13-03-96
-----	-----	-----	-----
WO 9627006 A	06-09-96	AU 5179196 A	18-09-96
-----	-----	-----	-----
WO 9623065 A	01-08-96	AU 4907496 A	14-08-96
-----	-----	-----	-----